[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medtronic Endovascular\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":130},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100642579","case-specific-health-care-professional-clinical-survey-for-concerto-versa-detachable-coils-100642579",false,"NCT07639853","Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils","Inclusion Criteria:\n\n1. Patient treated with Concerto Versa™ Detachable Coil is age ≥ 22 years at the time of procedure.\n2. Use of Concerto Versa™ Detachable Coil in accordance with the device labeling.\n3. Reporting of case within 72 hours of index procedure.","ALL","22 Years",{"count":18,"type":19},30,"ESTIMATED","OBSERVATIONAL","The purpose of the Case-Specific Health Care Professional (HCP) Clinical Survey for Concerto Versa™ Detachable Coils, also known as the Concerto Versa HCP Clinical Assessment, is to collect early clinical data from HCPs to assess clinical safety and performance of the Concerto Versa™ Detachable Coils, when used in accordance with approved device labeling per the Instructions for Use (IFU). Data collected will generate clinical evidence to quantitatively assess clinical safety and device performance for the purpose of obtaining European Union Medical Device Regulation (EU MDR) approval.",[23,24,25,26,27,28,29,30,31,32],"Arteriovenous Malformation","Gastrointestinal Bleed","Gastric Varices","Hemorrhoid","Pelvic Venous Disorders","Peripheral Aneurysms","Portal Vein Embolization","Type II Endoleak","Varicocele","Hemorrhage",[34,35,36,37,38,39,40,41,42],"Peripheral Vascular Disease","Vascular Disease","Arterial Embolization","Arteriovenous Embolization","Venous Embolization","Embolization Coils","Peripheral Embolization Coils","Peripheral Arterial Disease","Embolization","NOT_YET_RECRUITING","2026-06-11",{"date":46,"type":47},"2026-06-15","ACTUAL",{"date":49,"type":19},"2026-07",{"date":51,"type":19},"2026-11",{"name":53,"class":54},"Medtronic Endovascular","INDUSTRY",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":63,"conditions":64,"keywords":75,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100618724","case-specific-health-care-professional-clinical-survey-of-liberant-thrombectomy-system-100618724","NCT07335341","Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System","Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria:\n\n1. Patient treated is age ≥ 22 years at the time of procedure\n2. Use of Liberant in accordance with the device labeling within 72 hours of index procedure",{"count":62,"type":19},50,"The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems",[65,66,67,68,69,70,71,41,72,73,74],"Venous Embolism of Lower Extremities (Diagnosis)","Arterial Embolism and Thrombosis","Acute DVT of Lower Extremity","Chronic DVT of Lower Extremity","DVT","Deep Vein Thrombosis Leg","Thrombus in the Peripheral Venous Vasculature","Acute Limb Ischemia","Lower Extremity Acute Limb Ischemia","LE ALI",[76,77,78,79,80,81,82,83,84,41,85,86,87,88,89,90],"Thrombus in Peripheral Arterial Systems","Thrombectomy","Thrombosis","Venous Thrombosis","Aspiration Thrombectomy","Percutaneous Mechanical Thrombectomy","Arterial Occlusive Diseases","Vascular Diseases","Peripheral Vascular Diseases","Mechanical Thrombectomy","Aspiration","Liberant Thrombectomy System","adverse events","Excipio","Thrombus in Peripheral Venous Systems","RECRUITING","2026-06-05",{"date":94,"type":47},"2026-06-08",{"date":96,"type":47},"2026-02-24",{"date":98,"type":19},"2026-10",{"name":53,"class":54},2,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":119,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100573170","onyx-liquid-embolic-ide-clinical-study-100573170","NCT06742801","Onyx™ Liquid Embolic IDE Clinical Study","PELE IDE Clinical Study, Peripheral Onyx™ Liquid Embolic Safety and Effectiveness of The Onyx™ LES for Embolization of Arterial Hemorrhage in the Peripheral Vasculature","Inclusion Criteria:\n\n1. Patient is ≥ 22 years old.\n2. Active arterial bleeding in the peripheral vasculature confirmed by radiologic and\u002For endoscopic imaging and deemed suitable for embolization treatment by the investigator.\n\n   In this study, peripheral vasculature is defined as outside the brain and heart.\n3. Patient or legally authorized representative (LAR) is able to provide written consent to participate in the study.\n4. Life expectancy of \\>30 days, in the opinion of the investigator at the time of enrollment.\n5. Target treatment area is free from prior embolization treatment.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding.\n2. Symptoms of active infection.\n3. Patient is known to be participating in the study of an investigational drug, biologic, or device.\n4. Contrast allergy or other contraindication to angiography, CT, or catheterization, including contrast sensitivity that cannot be adequately treated prior to index procedure.\n5. Known allergy to components of Onyx™.\n6. Target vasculature unsuitable for the delivery of Onyx™ based upon physician assessment.\n7. More than 4 target lesions will require embolization, in the investigator's opinion after imaging-based assessment.",{"count":109,"type":19},119,"INTERVENTIONAL",[112],"NA","The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.",[115,116,117,118,32],"Peripheral Arterial Hemorrhage","Trauma","GI Bleed","Ulcer",[115,120],"Embolization treatment","2026-06-02",{"date":123,"type":47},"2026-06-03",{"date":125,"type":47},"2025-05-09",{"date":127,"type":19},"2027-05",{"name":53,"class":54},18,""]